drugset / Trial / NCT06641037

A Study of LY3866288 in Healthy Participants

NCT06641037

Phase 1 Completed 15 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to evaluate how well LY3866288 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3866288 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 9 weeks including screening.

Timeline

Start
2024-10-17
Primary completion
2024-12-02
Completion
2024-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Vepugratinib Unknown Oral

Indications

No indication recorded.